More on GLMD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.92 |
|
|||
| Open | $4.07 | ||||
| 52 Wk High | $9.70 | ||||
| 52 Wk Low | $2.78 | ||||
| Day High | $4.23 | ||||
| Day Low | $3.88 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,100 | ||||
- Form 6-K/A Galmed Pharmaceuticals For: Jul 22
- Form 6-K Galmed Pharmaceuticals For: Aug 19
- Galmed's Colospan reports feasibility data on tissue assessment tool
- Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
- Form 6-K Galmed Pharmaceuticals For: Aug 17
- Galmed's Aramchol shows added cell death in prostate cancer study
- Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
- Form 6-K Galmed Pharmaceuticals For: Aug 14
- Form 6-K Galmed Pharmaceuticals For: Jul 31
- Form 6-K Galmed Pharmaceuticals For: Jul 29
Entities mentioned with GLMD
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- Maxim Group | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
